Valo Health logo

Associate Director/Director, Head of DEL Discovery Strategy and Informatics

Valo Health

Lexington, MAOnsitePosted 1 day ago$190,000 - $210,000 USD
Full TimeDirector & AboveResearch & ScientistAI Biotech
Original posting ↗

Summary

Valo is seeking a Head of DEL, encompassing discovery strategy and selections, DEL chemistry and informatics to advance DNA-encoded library (DEL) technology as a core engine for initiating chemistry efforts across the portfolio. This leader will set the strategy for how DEL is deployed from target assessment and selection design through hit identification, off-DNA validation, and chemistry-start decisions. The role will lead a DEL team and partner with medicinal chemistry, computational chemistry, biology, protein sciences, and data science to turn DEL outputs into high-quality, model-ready data and chemically tractable starting points for the Opal Computational Platform.

Job description

The Role

Valo is seeking a Head of DEL, encompassing discovery strategy and selections, DEL chemistry and informatics to advance DNA-encoded library (DEL) technology as a core engine for initiating chemistry efforts across the portfolio. This leader will set the strategy for how DEL is deployed from target assessment and selection design through hit identification, off-DNA validation, and chemistry-start decisions. The role will lead a DEL team and partner with medicinal chemistry, computational chemistry, biology, protein sciences, and data science to turn DEL outputs into high-quality, model-ready data and chemically tractable starting points for the Opal Computational Platform.

What You'll Do

  • Set the strategic roadmap for using DEL as a first-line discovery approach to initiate chemistry campaigns across Valo's portfolio
  • Lead and develop a team of 4 to 5 scientists spanning DEL informatics, on-DNA chemistry, analysis, and discovery strategy
  • Define DEL deployment strategy, including target tractability, library fit, selection design, controls, counterscreens, and project-start decision criteria
  • Translate DEL selection outputs into actionable chemistry starts through enrichment analysis, hit-family triage, SAR hypotheses, off-DNA validation, and analog prioritization
  • Partner with medicinal chemistry, computational chemistry, biology, protein sciences, in vitro pharmacology and data science to advance DEL-derived hits into validated, chemically tractable series
  • Lead a team to build scalable DEL data workflows that generate high-quality, reusable, model-ready datasets for Opal and AI/ML-driven discovery
  • Scout, evaluate, and apply emerging DEL technologies, including next-generation library design, DNA-compatible chemistry, advanced selection methods, sequencing analytics, and ML-guided interpretation
  • Communicate strategy, tradeoffs, and recommendations to project teams and senior leaders to drive portfolio decisions

What You Bring

  • PhD in protein sciences, chemistry, computational chemistry, chemical biology, or related field with 8+ years of relevant industry experience for the application of DEL in a drug discovery setting
  • Demonstrated deep expertise in identifying and executing strategies for successful DEL campaigns for a variety of targets, including protein classes which are typically challenging for DEL selections
  • Strong understanding of DEL strategy from library design and selection through data analysis, hit identification, off-DNA validation, and chemistry-start planning
  • Demonstrated track record using DEL-derived data to initiate or advance medicinal chemistry programs and generate validated chemical matter
  • Strong grounding in protein sciences, organic chemistry, on-DNA chemistry, medicinal chemistry principles, cheminformatics, and large experimental datasets
  • Current knowledge of emerging DEL technologies and ability to assess which innovations should be adopted, partnered, or built internally
  • Experience working across AI/ML, data science, computational chemistry, biology, and protein sciences to turn DEL data into predictive insight and project decisions
  • Proven people leadership, cross-functional influence, and ability to communicate strategic recommendations clearly to senior stakeholders

Requirements

  • PhD in protein sciences, chemistry, computational chemistry, chemical biology, or related field
  • 8+ years of relevant industry experience applying DEL in a drug discovery setting
  • Demonstrated deep expertise in identifying and executing strategies for successful DEL campaigns across a variety of targets
  • Strong understanding of DEL strategy from library design and selection through data analysis, hit identification, off-DNA validation, and chemistry-start planning
  • Demonstrated track record using DEL-derived data to initiate or advance medicinal chemistry programs
  • Strong grounding in protein sciences, organic chemistry, on-DNA chemistry, medicinal chemistry principles, cheminformatics, and large experimental datasets
  • Current knowledge of emerging DEL technologies
  • Experience working across AI/ML, data science, computational chemistry, biology, and protein sciences
  • Proven people leadership, cross-functional influence, and communication to senior stakeholders
  • Permanent US work authorization without need for immediate or future sponsorship

Benefits

  • Healthcare coverage
  • Annual incentive program
  • Retirement benefits

Company overview

Valo Health is a pioneering technology company founded in 2019 that leverages artificial intelligence and large-scale human-centric data to transform drug discovery and development. Headquartered in Boston, Massachusetts with additional offices in Lexington, MA and New York, NY, the company has developed the Opal Computational Platform™, an end-to-end drug discovery and development platform with a unified architecture designed to accelerate the identification and development of life-changing therapeutics. Valo's innovative approach integrates human-centric data across the entire drug development lifecycle, aiming to significantly reduce costs, time, and failure rates while advancing a robust pipeline of programs initially focused on cardiovascular metabolic renal diseases, oncology, and neurodegenerative disorders. The company has raised substantial funding, including a $450M Series B round, and has established strategic partnerships with major pharmaceutical companies like Novo Nordisk and Merck KGaA to advance its AI-driven drug discovery capabilities.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.